Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
YM-155 Hydrochloride: Precision Survivin Inhibition in Compl
2026-04-30
Explore the unique capabilities of YM-155 hydrochloride as a potent survivin inhibitor for advanced apoptosis inhibitor research. This article bridges high-resolution in vitro assay insights with practical applications in challenging cancer models, offering perspectives unavailable in prior literature.
-
URB597 (KDS-4103): Optimizing FAAH Inhibition in Neuroplasti
2026-04-30
URB597, a potent and selective FAAH inhibitor, empowers precise endocannabinoid signaling studies and translational research in neuroplasticity and neuroinflammation. This article delivers actionable experimental workflows, advanced troubleshooting, and data-driven insights, leveraging the latest cross-disciplinary findings and APExBIO’s trusted quality.
-
WTAP-Mediated Glutaminase Splicing Suppresses Ferroptosis in
2026-04-29
This study uncovers how EGFR-driven phosphorylation of WTAP promotes a glutaminase splicing switch in hepatocellular carcinoma (HCC), enabling tumor cells to resist ferroptosis. The findings reveal a critical metabolic adaptation mechanism and highlight potential therapeutic targets for metabolic disorder and cancer research.
-
BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Parame
2026-04-29
BFH772 is a highly selective VEGFR2 inhibitor designed to enable researchers to modulate VEGFR2-driven angiogenesis with precision, particularly in tumor model systems. It is not recommended for workflows requiring water solubility or broad-spectrum kinase inhibition, due to its narrow selectivity and solubility profile.
-
Applied Workflows with Nadolol (SQ-11725) in Cardiovascular
2026-04-28
Nadolol (SQ-11725) enables precise, reproducible beta-adrenergic blockade for hypertension, angina pectoris, and vascular headache models. This article guides researchers through optimized protocols, troubleshooting strategies, and the impact of transporter-mediated pharmacokinetics, leveraging both cutting-edge literature and real-world lab experience.
-
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine: Rigorous Contr
2026-04-28
PP 3, a high-purity research use only chemical, redefines specificity in Src kinase signaling pathway research as a negative control for PP 2. This guide offers actionable workflow enhancements, protocol precision, and troubleshooting rooted in the latest vascular signaling insights.
-
Haloprogin: Precision Antimicrobial Profiling for Research I
2026-04-27
Explore Haloprogin, a broad-spectrum antimicrobial agent, through the lens of quantitative assay optimization and translational relevance. This article offers a unique scientific analysis of Haloprogin’s protocol parameters, mechanistic insights, and how it informs rigorous experimental design.
-
Ionizing Radiation Alters Neuronal Differentiation via PI3K-
2026-04-27
This study reveals that ionizing radiation (IR) drives altered neuronal differentiation in C17.2 mouse neural stem-like cells through a PI3K-STAT3-mGluR1 signaling pathway. The findings provide mechanistic insight into how IR exposure may impact neural development, with significant implications for understanding neural toxicity and therapeutic side effects in brain radiotherapy.
-
5-Azacytidine in DNA Demethylation: Mechanistic Depth & Tran
2026-04-26
Explore the advanced mechanism of 5-Azacytidine as a DNA demethylation agent, with new perspectives on epigenetic regulation and practical assay design. This article provides unique insights for cancer research beyond conventional overviews.
-
Pregnenolone Carbonitrile in CYP3A Induction & Liver Fibrosi
2026-04-25
Pregnenolone Carbonitrile is a benchmark tool for dissecting xenobiotic metabolism and antifibrotic mechanisms. This guide translates recent advances—including pharmacokinetic insights from MASLD models—into practical, reproducible workflows for hepatic detoxification and fibrosis assays.
-
Glabridin-Gold(I) Complex Targets TrxR/MAPK for Antitumor Im
2026-04-24
This study introduces a novel glabridin–gold(I) complex (6d) as an immunomodulatory agent that synergistically targets thioredoxin reductase (TrxR) and MAPK pathways. The findings highlight enhanced dendritic cell maturation, reduced immunosuppressive cells, and improved antitumor immune responses, with implications for advancing cancer immunotherapy strategies.
-
MiR-3180 Suppresses HCC by Targeting SCD1 and CD36 Lipid Pat
2026-04-24
Hong et al. (2023) identified miR-3180 as a dual regulator of lipid synthesis and uptake in hepatocellular carcinoma (HCC), acting through suppression of SCD1 and CD36. This finding advances understanding of metabolic regulation in HCC and highlights miR-3180 as a promising therapeutic and prognostic biomarker.
-
TPPU: Precision Soluble Epoxide Hydrolase Inhibitor for Infl
2026-04-23
TPPU, a nanomolar soluble epoxide hydrolase inhibitor, empowers researchers to dissect lipid signaling in inflammation, pain, and bone metabolism with unprecedented potency and pharmacokinetics. Drawing on the latest liver-bone axis discoveries, this guide details optimized protocols and troubleshooting strategies for deploying TPPU in translational models.
-
EZ Cap EGFP mRNA 5-moUTP: Optimizing Fluorescent Reporter Wo
2026-04-23
EZ Cap™ EGFP mRNA (5-moUTP) offers high-efficiency, low-immunogenicity fluorescent protein expression, streamlining both in vitro and in vivo gene regulation studies. Its advanced modifications and Cap 1 structure enable robust signal, improved stability, and reduced immune activation, making it a superior tool for precise mRNA delivery and translation assays.
-
MLN8237 (Alisertib): Precision Aurora A Inhibition in Cancer
2026-04-22
MLN8237 (Alisertib) empowers cancer biologists to dissect mitotic control and apoptosis with unmatched specificity, thanks to its nanomolar potency and selectivity for Aurora A kinase. This guide details optimized experimental workflows, troubleshooting strategies, and practical lessons drawn from recent advances in trained immunity research.